Trial Profile
Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Delayed graft function
- Focus Registrational; Therapeutic Use
- Acronyms EPURE TRANSPLANT
- 09 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2022 Planned End Date changed from 1 Jul 2030 to 1 Aug 2031.
- 21 Jun 2017 Planned End Date changed from 1 May 2030 to 1 Jul 2030.